高频多模式培训,重点是帕金森病患者的太极拳:试点研究
Ketevan Toloraia1,2, Ute Gschwandtner1,2, Peter Fuhr1,2
1Department of Clinical Research and Neurology, University Hospital Basel, Basel, Switzerland.
Frontiers in aging neuroscience
|March 1, 2024
概括
高频多模式训练改善了帕金森病 (PD) 患者的认知和运动功能. 这项密集的计划增强了记忆力,视觉空间技能和步行稳定性,为PD管理提供了有前途的方法.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 康复医学 康复医学 康复医学
背景情况:
- 认知能力下降是帕金森病 (PD) 的重要并发症,降低了患者的生活质量.
- 目前对PD认知衰退的治疗方法有限,需要对有效干预措施的研究.
- 多模式培训提供了一个潜在的策略,以解决PD中的运动和认知障碍.
研究的目的:
- 评估高频,密集的多模式训练在增强PD患者的运动和认知功能的有效性.
- 为了比较综合多式联络干预与标准认知培训计划的效果.
主要方法:
- 招募了28名异形性PD患者,15名在干预组,13名在对照组.
- 干预组接受了4周的太极拳,基于智能手机的语音和认知训练.
- 对照组接受了计算机辅助的认知训练,并使用重复测量ANOVA分析数据.
主要成果:
- 干预组在口头和形象情节性记忆和视觉空间功能方面表现出显著的改善.
- 与对照组相比,干预组在视觉空间功能和图形情节性记忆方面表现出更大的收益.
- 在步态和稳定性 (Tinetti移动性测试) 中观察到显著改善,在6个月的随访中持续.
结论:
- 在帕金森病患者中,强化,高频多模式训练可以有效地改善认知功能,包括记忆和视觉空间能力.
- 这种训练方法还可以增强运动功能,如步态和稳定性.
- 这些发现表明,多式联络培训是治疗帕金森病症状的有益策略.
相关概念视频
Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
Parkinson's Disease: Overview
544
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
544
Alzheimer's Disease: Treatment
188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188


